

REMARKS

Applicants have amended the specification by providing a substitute sequence listing to correct section <223> for SEQ ID NO: 5 in accordance with 37 C.F.R. §§ 1.821 through 1.825.

In accordance with 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d), the sequence listing submitted herewith is in .txt format and is being filed electronically; therefore, the sequence listing satisfies the requirement as the computer readable copy and as the paper copy since they are the same.

No new matter is introduced by way of these amendments.

In light of the foregoing amendments to the application, Applicants submit that the application is now in full compliance with 37 C.F.R. §§ 1.821 through 1.825.

In the event the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 07-1048, referencing Docket No. GC800-2-US.

Respectfully submitted,

Date: September 16, 2008

/Jill A. Jacobson/

Jill A. Jacobson

Registration No. 40,030

Danisco US Inc., Genencor Division
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-4072
Fax: 650-845-6504